Analysts’ Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and Regeneron (REGN) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie (ABBV)
Guggenheim analyst Vamil Divan reiterated a Buy rating on AbbVie today and set a price target of $249.00. The company’s shares closed last Thursday at $200.95.
According to TipRanks.com, Divan is a 5-star analyst with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $252.95, which is a 25.8% upside from current levels. In a report issued on April 20, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $262.00 price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
Piper Sandler analyst Biren Amin maintained a Buy rating on Regeneron today and set a price target of $875.00. The company’s shares closed last Thursday at $766.02.
According to TipRanks.com, Amin is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $877.32 average price target, which is a 16.8% upside from current levels. In a report issued on April 13, Truist Financial also maintained a Buy rating on the stock.
Read More on ABBV:
